

## ASX ANNOUNCEMENT

### RIGHTS ISSUE – \$2.8M PARTIALLY UNDERWRITTEN OFFER AND REVISED TIMETABLE

**13 July 2015:** Analytica Ltd (ASX: ALT) manufacturer of the PeriCoach System, is pleased to advise the market that the rights offer announced last week aiming to raise up to \$3.7m is to be partially underwritten to \$2.8m by the Lead Manager Patersons Securities Limited.

The company is finalising a prospectus setting out full details of the renounceable pro-rata rights issue. It is anticipated that the prospectus will be lodged and released to the market before commencement of trading on Tuesday 14th July. A revised timetable is below.

Lodgement of Prospectus with ASIC and announcement of Offer	Tuesday 14 July 2015
Existing shares quoted 'ex' rights / Rights trading commences	Thursday 16 July 2015
Record Date - 7.00pm (Sydney time)	Monday 20 July 2015
Despatch of Prospectus and Entitlement and Acceptance Forms Offer Opening Date	Thursday 23 July 2015
Rights trading ends	Monday 27 July 2015
Closing Date – last date for acceptance and payment in full	5.00pm (Sydney time) Tuesday 4 August 2015
Announcement of shortfall (if any) under the Offers	Thursday 6 August 2015
Allotment and issue of New Shares and Attaching Options	Tuesday 11 August 2015
Despatch date of holding statements	Wednesday 12 August 2015
Normal trading of New Shares and options commences	Wednesday 12 August 2015

Bryan Dulhunty

Company Secretary



For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. The product has USFDA 510(k) clearance. The product has been on sale in Australia and New Zealand since January, and recently launched in the UK and Ireland, and in the USA. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.

